We present a high-resolution x-ray study of the effects of disorder due to random crosslinking on the one-dimensional translational ordering in smectic elastomers. At a small crosslink density of about 5%, the elastomer network stabilizes the smectic structure against layer-displacement fluctuations, and the algebraically decaying layer ordering extends up to several micrometers. With increasing concentration of crosslinks, the finite size of these domains is strongly reduced, indicating that disordering takes over. Finally, at a crosslink concentration of 20%, the structure factor can be described by a Lorentzian, which signals extended short-range correlations. The findings are discussed in terms of recent theories of randomly quenched disorder.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1103/PhysRevLett.93.185702 | DOI Listing |
J Voice
January 2025
Department of Surgery, UMONS Research Institute for Health Sciences and Technology, University of Mons (UMons), Mons, Belgium; Division of Laryngology and Bronchoesophagology, Department of Otolaryngology Head Neck Surgery, EpiCURA Hospital, Baudour, Belgium; Department of Otolaryngology-Head and Neck Surgery, Foch Hospital, School of Medicine, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), Paris, France; Department of Otolaryngology, Elsan Hospital, Paris, France. Electronic address:
Background: Voice analysis has emerged as a potential biomarker for mood state detection and monitoring in bipolar disorder (BD). The systematic review aimed to summarize the evidence for voice analysis applications in BD, examining (1) the predictive validity of voice quality outcomes for mood state detection, and (2) the correlation between voice parameters and clinical symptom scales.
Methods: A PubMed, Scopus, and Cochrane Library search was carried out by two investigators for publications investigating voice quality in BD according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statements.
Diabetes Metab
January 2025
Division of Diabetes, Nutrition and Metabolic Disorders, CHU Liège, Liège, Belgium; Division of Clinical Pharmacology, Centre for Interdisciplinary Research on Medicines (CIRM), Liège University, Liège, Belgium. Electronic address:
Background: Obesity is an increasing public health problem because of its high prevalence and associated morbidity and mortality. Two weight-loss strategies are currently used, either bariatric surgery or pharmacological therapy with glucagon-like peptide-1 receptor agonists (GLP-1RAs). Preclinical studies in rodents suggested an increased risk of additive disorders after bariatric surgery contrasting with a reduced risk with GLP-1RAs.
View Article and Find Full Text PDFJ Steroid Biochem Mol Biol
January 2025
Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China; Beijing Institute of Traditional Chinese Medicine, Beijing, China. Electronic address:
Vitiligo is a common chronic skin depigmentation disorder that seriously decreases the patients' overall quality of life. Human blood metabolites could contribute to unraveling the underlying biological mechanisms of vitiligo. We used GWAS summary statistics to assess the causal association between genetically predicted 1,400 serum metabolites and vitiligo risk by Mendelian randomization (MR).
View Article and Find Full Text PDFJ Affect Disord
January 2025
Department of Psychiatry and Psychotherapy, University of Marburg, Germany; Center for Mind, Brain and Behavior (CMBB), University of Marburg, Germany.
Background: Major depressive disorder (MDD) comes along with an increased risk of recurrence and poor course of illness. Machine learning has recently shown promise in the prediction of mental illness, yet models aiming to predict MDD course are still rare and do not quantify the predictive value of established MDD recurrence risk factors.
Methods: We analyzed N = 571 MDD patients from the Marburg-Münster Affective Disorder Cohort Study (MACS).
Lancet Rheumatol
January 2025
Department of Rheumatology, Université de Bretagne Occidentale, CHU Brest, INSERM (U1227), LabEx IGO Brest, France.
Background: Moderate doses of glucocorticoids result in improvements in nearly all patients with polymyalgia rheumatica, but related adverse events are common in older individuals. We aimed to evaluate whether treatment with baricitinib (a Janus kinase 1/2 inhibitor) results in disease control without the use of oral glucocorticoids in people with recent-onset polymyalgia rheumatica.
Methods: We conducted a randomised, double-blind, placebo-controlled, parallel-group trial at six expert centres in France.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!